Ally Olotu, Ph.D., Gregory Fegan, Ph.D., Juliana Wambua, M.Sc, George Nyangweso, B.Sc., Amanda Leach, M.R.C.P.C.H., Marc Lievens, M.Sc., David C. Kaslow, M.D., Patricia Njuguna, M.Med., Kevin Marsh, F.R.C.P., and Philip Bejon, Ph.D.

RTS,S/AS01 is a malaria vaccine candidate that has undergone phase 3 evaluation across several sites in Africa that have varying intensities of malaria transmission.